The antigen-binding site of the antibody has a unique structure that allows it to bind antigen in a highly specific manner. Functional and structural studies of two potent antibodies isolated from ...
The first-in-class and so far best-in-class PD-1xVEGF bispecific antibody ivonescimab has set the bar for competitors in the pipeline for a superior clinical profile compared with anti-PD-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback